Lexicon Pharmaceuticals Announces Publication of Positive Data for Zynquista™ (Sotagliflozin) on Cardiorenal Clinical Biomarkers in Adults With Type 1 Diabetes
Lexicon Pharmaceuticals, Inc. (LXRX)
Last lexicon pharmaceuticals, inc. earnings: 4/27 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
lexpharma.com/investors
Company Research
Source: GlobeNewswire
Changes in Clinical Biomarkers Suggestive of Favorable Effects on Kidney Function in Patients with Type 1 Diabetes Results Recently Published in Diabetes Care THE WOODLANDS, Texas, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced positive 52-week cardiorenal results from a pooled analysis from the inTandem1 and inTandem2 studies of Zynquista™ (sotagliflozin) in adults with type 1 diabetes. Zynquista demonstrated changes in clinical biomarkers such as estimated glomerular filtration rate (eGFR), hematocrit, serum albumin, uric acid, systolic blood pressure and urinary albumin-to-creatinine ratio (UACR) that suggest Zynquista may reduce cardiovascular risk and progression of chronic kidney disease. Zynquista was associated with short- and long-term renal hemodynamic changes. Importantly, after cessation of 52 weeks of therapy, eGFR was comparable to baseline and significantly higher than placebo in Zynquista-treated patients. These res
Show less
Read more
Impact Snapshot
Event Time:
LXRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LXRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LXRX alerts
High impacting Lexicon Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
LXRX
News
- Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA [Yahoo! Finance]Yahoo! Finance
- Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDAGlobeNewswire
- Lexicon Appoints Ivan H. Cheung to Board of Directors [Yahoo! Finance]Yahoo! Finance
- Lexicon Appoints Ivan H. Cheung to Board of DirectorsGlobeNewswire
- Lexicon Pharmaceuticals (NASDAQ:LXRX investor three-year losses grow to 80% as the stock sheds US$107m this past week [Yahoo! Finance]Yahoo! Finance
LXRX
Earnings
- 11/12/24 - Miss
LXRX
Sec Filings
- 11/20/24 - Form 8-K
- 11/14/24 - Form SC
- 11/13/24 - Form 10-Q
- LXRX's page on the SEC website